ID   APOB_HUMAN              Reviewed;        4563 AA.
AC   P04114; O00502; P78479; P78480; P78481; Q13779; Q13785; Q13786;
AC   Q13787; Q13788; Q4ZG63; Q53QC8; Q7Z600; Q9UMN0;
DT   01-NOV-1986, integrated into UniProtKB/Swiss-Prot.
DT   13-JUL-2010, sequence version 2.
DT   10-MAY-2017, entry version 208.
DE   RecName: Full=Apolipoprotein B-100;
DE            Short=Apo B-100;
DE   Contains:
DE     RecName: Full=Apolipoprotein B-48;
DE              Short=Apo B-48;
DE   Flags: Precursor;
GN   Name=APOB;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND VARIANTS ASN-273; GLU-1218; CYS-1422;
RP   RP VAL-2092; VAL-2313; THR-2365; GLN-2680; HIS-3319; LYS-3427;
RP   GLU-3432; THR-3732; LEU-3949; PHE-3964; LYS-4181 AND ASN-4338.
RX   PubMed=3763409; DOI=10.1093/nar/14.18.7501;
RA   Knott T.C., Wallis S.C., Powell L.M., Pease R.J., Lusis A.J.,
RA   Blackhart B., McCarthy B.J., Mahley R.W., Levy-Wilson B., Scott J.;
RT   "Complete cDNA and derived protein sequence of human apolipoprotein B-
RT   100.";
RL   Nucleic Acids Res. 14:7501-7503(1986).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS CYS-1422; VAL-2313;
RP   HIS-3319; LYS-3427; GLU-3432 AND ASN-4338.
RX   PubMed=3652907; DOI=10.1089/dna.1987.6.363;
RA   Ludwig E.H., Blackhart B.D., Pierotti V.R., Caiati L., Fortier C.,
RA   Knott T., Scott J., Mahley R.W., Levy-Wilson B., McCarthy B.J.;
RT   "DNA sequence of the human apolipoprotein B gene.";
RL   DNA 6:363-372(1987).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND VARIANTS ILE-98; VAL-618; CYS-1422;
RP   VAL-2313; HIS-3319; LYS-3427; GLU-3432 AND ASN-4338.
RX   PubMed=3759943;
RA   Chen S.-H., Yang C.-Y., Chen P.-F., Setzer D., Tanimura M., Li W.-H.,
RA   Gotto A.M. Jr., Chan L.;
RT   "The complete cDNA and amino acid sequence of human apolipoprotein B-
RT   100.";
RL   J. Biol. Chem. 261:12918-12921(1986).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND VARIANTS CYS-1422; ASN-2037; VAL-2313;
RP   HIS-3319; LYS-3427; GLU-3432; LEU-3949; LYS-4181 AND ASN-4338.
RX   PubMed=3464946; DOI=10.1073/pnas.83.21.8142;
RA   Law S.W., Grant S.M., Higuchi K., Hospattankar A.V., Lackner K.J.,
RA   Lee N., Brewer H.B. Jr.;
RT   "Human liver apolipoprotein B-100 cDNA: complete nucleic acid and
RT   derived amino acid sequence.";
RL   Proc. Natl. Acad. Sci. U.S.A. 83:8142-8146(1986).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA], NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-40,
RP   AND VARIANTS VAL-618; CYS-1422; VAL-2313; HIS-3319; LYS-3427;
RP   GLU-3432; THR-3732; LEU-3949; PHE-3964; LYS-4181 AND ASN-4338.
RX   PubMed=3030729;
RA   Cladaras C., Hadzopoulou-Cladaras M., Nolte R.T., Atkinson D.,
RA   Zannis V.I.;
RT   "The complete sequence and structural analysis of human apolipoprotein
RT   B-100: relationship between apoB-100 and apoB-48 forms.";
RL   EMBO J. 5:3495-3507(1986).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS CYS-1422; VAL-2313 AND
RP   ASN-4338.
RG   SeattleSNPs variation discovery resource;
RL   Submitted (JUN-2003) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15815621; DOI=10.1038/nature03466;
RA   Hillier L.W., Graves T.A., Fulton R.S., Fulton L.A., Pepin K.H.,
RA   Minx P., Wagner-McPherson C., Layman D., Wylie K., Sekhon M.,
RA   Becker M.C., Fewell G.A., Delehaunty K.D., Miner T.L., Nash W.E.,
RA   Kremitzki C., Oddy L., Du H., Sun H., Bradshaw-Cordum H., Ali J.,
RA   Carter J., Cordes M., Harris A., Isak A., van Brunt A., Nguyen C.,
RA   Du F., Courtney L., Kalicki J., Ozersky P., Abbott S., Armstrong J.,
RA   Belter E.A., Caruso L., Cedroni M., Cotton M., Davidson T., Desai A.,
RA   Elliott G., Erb T., Fronick C., Gaige T., Haakenson W., Haglund K.,
RA   Holmes A., Harkins R., Kim K., Kruchowski S.S., Strong C.M.,
RA   Grewal N., Goyea E., Hou S., Levy A., Martinka S., Mead K.,
RA   McLellan M.D., Meyer R., Randall-Maher J., Tomlinson C.,
RA   Dauphin-Kohlberg S., Kozlowicz-Reilly A., Shah N.,
RA   Swearengen-Shahid S., Snider J., Strong J.T., Thompson J., Yoakum M.,
RA   Leonard S., Pearman C., Trani L., Radionenko M., Waligorski J.E.,
RA   Wang C., Rock S.M., Tin-Wollam A.-M., Maupin R., Latreille P.,
RA   Wendl M.C., Yang S.-P., Pohl C., Wallis J.W., Spieth J., Bieri T.A.,
RA   Berkowicz N., Nelson J.O., Osborne J., Ding L., Meyer R., Sabo A.,
RA   Shotland Y., Sinha P., Wohldmann P.E., Cook L.L., Hickenbotham M.T.,
RA   Eldred J., Williams D., Jones T.A., She X., Ciccarelli F.D.,
RA   Izaurralde E., Taylor J., Schmutz J., Myers R.M., Cox D.R., Huang X.,
RA   McPherson J.D., Mardis E.R., Clifton S.W., Warren W.C.,
RA   Chinwalla A.T., Eddy S.R., Marra M.A., Ovcharenko I., Furey T.S.,
RA   Miller W., Eichler E.E., Bork P., Suyama M., Torrents D.,
RA   Waterston R.H., Wilson R.K.;
RT   "Generation and annotation of the DNA sequences of human chromosomes 2
RT   and 4.";
RL   Nature 434:724-731(2005).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 1-1670, AND VARIANTS ILE-98; CYS-1422
RP   AND ASP-1670.
RX   PubMed=3461454; DOI=10.1073/pnas.83.15.5678;
RA   Protter A.A., Hardman D.A., Sato K.Y., Schilling J.W., Yamanaka M.,
RA   Hort Y.J., Hjerrild K.A., Chen G.C., Kane J.P.;
RT   "Analysis of cDNA clones encoding the entire B-26 region of human
RT   apolipoprotein B.";
RL   Proc. Natl. Acad. Sci. U.S.A. 83:5678-5682(1986).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 1-291.
RX   PubMed=3513177; DOI=10.1073/pnas.83.5.1467;
RA   Protter A.A., Hardman D.A., Schilling J.W., Miller J., Appleby V.,
RA   Chen G.C., Kirsher S.W., McEnroe G., Kane J.P.;
RT   "Isolation of a cDNA clone encoding the amino-terminal region of human
RT   apolipoprotein B.";
RL   Proc. Natl. Acad. Sci. U.S.A. 83:1467-1471(1986).
RN   [10]
RP   PARTIAL PROTEIN SEQUENCE, DISULFIDE BONDS, AND VARIANT ILE-98.
RX   PubMed=2115173; DOI=10.1073/pnas.87.14.5523;
RA   Yang C.Y., Kim T.W., Weng S.A., Lee B.R., Yang M.L., Gotto A.M. Jr.;
RT   "Isolation and characterization of sulfhydryl and disulfide peptides
RT   of human apolipoprotein B-100.";
RL   Proc. Natl. Acad. Sci. U.S.A. 87:5523-5527(1990).
RN   [11]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 485-1044.
RC   TISSUE=Liver;
RX   PubMed=3001697; DOI=10.1073/pnas.82.24.8340;
RA   Law S.W., Lackner K.J., Hospattankar A.V., Anchors J.M.,
RA   Sakaguchi A.Y., Naylor S.L., Brewer H.B. Jr.;
RT   "Human apolipoprotein B-100: cloning, analysis of liver mRNA, and
RT   assignment of the gene to chromosome 2.";
RL   Proc. Natl. Acad. Sci. U.S.A. 82:8340-8344(1985).
RN   [12]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 709-906.
RX   PubMed=3860836; DOI=10.1073/pnas.82.15.4983;
RA   Deeb S.S., Motulsky A.G., Albers J.J.;
RT   "A partial cDNA clone for human apolipoprotein B.";
RL   Proc. Natl. Acad. Sci. U.S.A. 82:4983-4986(1985).
RN   [13]
RP   PROTEIN SEQUENCE OF 873-896 AND 3113-3137.
RX   PubMed=6373369; DOI=10.1016/0014-5793(84)81378-2;
RA   LeBoeuf R.C., Miller C., Shively J.E., Schumaker V.N., Balla M.A.,
RA   Lusis A.J.;
RT   "Human apolipoprotein B: partial amino acid sequence.";
RL   FEBS Lett. 170:105-108(1984).
RN   [14]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1042-1232.
RX   PubMed=2567736;
RA   Huang L.S., Ripps M.E., Korman S.H., Deckelbaum R.J., Breslow J.L.;
RT   "Hypobetalipoproteinemia due to an apolipoprotein B gene exon 21
RT   deletion derived by Alu-Alu recombination.";
RL   J. Biol. Chem. 264:11394-11400(1989).
RN   [15]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 1282-4503, AND VARIANTS CYS-1422;
RP   VAL-2313; HIS-3319; LYS-3427; GLU-3432; THR-3732 AND ASN-4338.
RX   PubMed=2883086; DOI=10.1016/0378-1119(86)90383-5;
RA   Carlsson P., Darnfors C., Olofsson S.O., Bjursell G.;
RT   "Analysis of the human apolipoprotein B gene; complete structure of
RT   the B-74 region.";
RL   Gene 49:29-51(1986).
RN   [16]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 1671-2398, AND VARIANT VAL-2313.
RX   PubMed=3676265; DOI=10.1021/bi00391a040;
RA   Hardman D.A., Protter A.A., Chen G.C., Schilling J.W., Sato K.Y.,
RA   Lau K., Yamanaka M., Mikita T., Miller J., Crisp T., McEnroe G.,
RA   Scarborough R.M., Kane J.P.;
RT   "Structural comparison of human apolipoproteins B-48 and B-100.";
RL   Biochemistry 26:5478-5486(1987).
RN   [17]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 1937-2018 AND 3811-4334.
RX   PubMed=3841204; DOI=10.1093/nar/13.24.8813;
RA   Carlsson P., Olofsson S.O., Bondjers G., Darnfors C., Wiklund O.,
RA   Bjursell G.;
RT   "Molecular cloning of human apolipoprotein B cDNA.";
RL   Nucleic Acids Res. 13:8813-8826(1985).
RN   [18]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 2115-2179.
RC   TISSUE=Small intestine;
RX   PubMed=3621347; DOI=10.1016/0092-8674(87)90510-1;
RA   Powell L.M., Wallis S.C., Pease R.J., Edwards Y.H., Knott T.J.,
RA   Scott J.;
RT   "A novel form of tissue-specific RNA processing produces
RT   apolipoprotein-B48 in intestine.";
RL   Cell 50:831-840(1987).
RN   [19]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 2127-2179.
RX   PubMed=2450346; DOI=10.1073/pnas.85.6.1772;
RA   Higuchi K., Hospattankar A.V., Law S.W., Meglin N., Cortright J.,
RA   Brewer H.B. Jr.;
RT   "Human apolipoprotein B (apoB) mRNA: identification of two distinct
RT   apoB mRNAs, an mRNA with the apoB-100 sequence and an apoB mRNA
RT   containing a premature in-frame translational stop codon, in both
RT   liver and intestine.";
RL   Proc. Natl. Acad. Sci. U.S.A. 85:1772-1776(1988).
RN   [20]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 2129-2235.
RX   PubMed=3426612; DOI=10.1016/0006-291X(87)90537-7;
RA   Hardman D.A., Protter A.A., Schilling J.W., Kane J.P.;
RT   "Carboxyl terminal analysis of human B-48 protein confirms the novel
RT   mechanism proposed for chain termination.";
RL   Biochem. Biophys. Res. Commun. 149:1214-1219(1987).
RN   [21]
RP   PROTEIN SEQUENCE OF 2169-2179.
RX   PubMed=2445342; DOI=10.1016/0006-291X(87)91107-7;
RA   Hospattankar A.V., Higuchi K., Law S.W., Meglin N., Brewer H.B. Jr.;
RT   "Identification of a novel in-frame translational stop codon in human
RT   intestine apoB mRNA.";
RL   Biochem. Biophys. Res. Commun. 148:279-285(1987).
RN   [22]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 3056-3159.
RX   PubMed=3903660; DOI=10.1093/nar/13.19.6937;
RA   Mehrabian M., Schumaker V.N., Fareed G.C., West R., Johnson D.F.,
RA   Kirchgessner T.G., Lin H.-C., Wang X., Ma Y., Mendiaz E., Lusis A.J.;
RT   "Human apolipoprotein B: identification of cDNA clones and
RT   characterization of mRNA.";
RL   Nucleic Acids Res. 13:6937-6953(1985).
RN   [23]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 3109-4563, AND VARIANTS HIS-3319;
RP   LYS-3427; GLU-3432; THR-3732; LEU-3949; PHE-3964; LYS-4181 AND
RP   ASN-4338.
RX   PubMed=2994225; DOI=10.1126/science.2994225;
RA   Knott T.J., Rall S.C. Jr., Innerarity T.L., Jacobson S.F., Urdea M.S.,
RA   Levy-Wilson B., Powell L.M., Pease R.J., Eddy R., Nakai H., Byers M.,
RA   Priestley L.M., Robertson E., Rall L.B., Betsholtz C., Shows T.B.,
RA   Mahley R.W., Scott J.;
RT   "Human apolipoprotein B: structure of carboxyl-terminal domains, sites
RT   of gene expression, and chromosomal localization.";
RL   Science 230:37-43(1985).
RN   [24]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 3728-4563, AND VARIANT ASN-4338.
RX   PubMed=2932736; DOI=10.1073/pnas.82.21.7265;
RA   Wei C.F., Chen S.H., Yang C.Y., Marcel Y.L., Milne R.W., Li W.H.,
RA   Sparrow J.T., Gotto A.M. Jr., Chan L.;
RT   "Molecular cloning and expression of partial cDNAs and deduced amino
RT   acid sequence of a carboxyl-terminal fragment of human apolipoprotein
RT   B-100.";
RL   Proc. Natl. Acad. Sci. U.S.A. 82:7265-7269(1985).
RN   [25]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 3846-4298, AND VARIANTS LEU-3949;
RP   PHE-3964 AND LYS-4181.
RC   TISSUE=Liver;
RX   PubMed=3841481; DOI=10.1016/0021-9150(85)90073-5;
RA   Shoulders C.C., Myant N.B., Sidoli A., Rodriguez J.C., Cortese C.,
RA   Baralle F.E., Cortese R.;
RT   "Molecular cloning of human LDL apolipoprotein B cDNA. Evidence for
RT   more than one gene per haploid genome.";
RL   Atherosclerosis 58:277-289(1985).
RN   [26]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 4217-4563.
RX   PubMed=3024665;
RA   Pfitzner R., Wagener R., Stoffel W.;
RT   "Isolation, expression and characterization of a human apolipoprotein
RT   B 100-specific cDNA clone.";
RL   Biol. Chem. Hoppe-Seyler 367:1077-1083(1986).
RN   [27]
RP   PARTIAL PROTEIN SEQUENCE, AND IDENTIFICATION OF APO-B48.
RX   PubMed=3659919; DOI=10.1126/science.3659919;
RA   Chen S.-H., Habib G., Yang C.-H., Gu Z.-W., Lee B.R., Weng S.-H.,
RA   Silberman S.R., Cai S.-J., Deslypere J.P., Rosseneu M.,
RA   Gotto A.M. Jr., Li W.-H., Chan L.;
RT   "Apolipoprotein B-48 is the product of a messenger RNA with an organ-
RT   specific in-frame stop codon.";
RL   Science 238:363-366(1987).
RN   [28]
RP   DOMAINS.
RX   PubMed=3773997; DOI=10.1038/323734a0;
RA   Knott T.C., Pease R.J., Powell L.M., Wallis S.C., Rall S.C. Jr.,
RA   Innerarity T.L., Blackhart B., Taylor W.R., Marcel Y., Milne R.,
RA   Johnson D., Fuller M., Lusis A.J., McCarthy B.J., Mahley R.W.,
RA   Levy-Wilson B., Scott J.;
RT   "Complete protein sequence and identification of structural domains of
RT   human apolipoprotein B.";
RL   Nature 323:734-738(1986).
RN   [29]
RP   DOMAINS.
RX   PubMed=3095664; DOI=10.1038/323738a0;
RA   Yang C.-Y., Chen S.-H., Gianturco S.H., Bradley W.A., Sparrow J.T.,
RA   Tanimura M., Li W.-H., Sparrow D.A., Deloof H., Rosseneu M.,
RA   Lee F.-S., Gu Z.-W., Gotto A.M. Jr., Chan L.;
RT   "Sequence, structure, receptor-binding domains and internal repeats of
RT   human apolipoprotein B-100.";
RL   Nature 323:738-742(1986).
RN   [30]
RP   CALCIUM-BINDING.
RX   PubMed=3087360; DOI=10.1016/0006-291X(86)91237-4;
RA   Dashti N., Lee D.M., Mok T.;
RT   "Apolipoprotein B is a calcium binding protein.";
RL   Biochem. Biophys. Res. Commun. 137:493-499(1986).
RN   [31]
RP   PALMITOYLATION AT CYS-1112.
RX   PubMed=10679026; DOI=10.1091/mbc.11.2.721;
RA   Zhao Y., McCabe J.B., Vance J., Berthiaume L.G.;
RT   "Palmitoylation of apolipoprotein B is required for proper
RT   intracellular sorting and transport of cholesteroyl esters and
RT   triglycerides.";
RL   Mol. Biol. Cell 11:721-734(2000).
RN   [32]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-3358.
RC   TISSUE=Plasma;
RX   PubMed=14760718; DOI=10.1002/pmic.200300556;
RA   Bunkenborg J., Pilch B.J., Podtelejnikov A.V., Wisniewski J.R.;
RT   "Screening for N-glycosylated proteins by liquid chromatography mass
RT   spectrometry.";
RL   Proteomics 4:454-465(2004).
RN   [33]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-1523; ASN-2982; ASN-3465
RP   AND ASN-3895.
RC   TISSUE=Plasma;
RX   PubMed=16335952; DOI=10.1021/pr0502065;
RA   Liu T., Qian W.-J., Gritsenko M.A., Camp D.G. II, Monroe M.E.,
RA   Moore R.J., Smith R.D.;
RT   "Human plasma N-glycoproteome analysis by immunoaffinity subtraction,
RT   hydrazide chemistry, and mass spectrometry.";
RL   J. Proteome Res. 4:2070-2080(2005).
RN   [34]
RP   INDUCTION, AND IDENTIFICATION BY MASS SPECTROMETRY.
RX   PubMed=16548883; DOI=10.1111/j.1462-5822.2005.00644.x;
RA   Leong W.F., Chow V.T.;
RT   "Transcriptomic and proteomic analyses of rhabdomyosarcoma cells
RT   reveal differential cellular gene expression in response to
RT   enterovirus 71 infection.";
RL   Cell. Microbiol. 8:565-580(2006).
RN   [35]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-185; ASN-1523; ASN-2239;
RP   ASN-2779; ASN-2982; ASN-3101; ASN-3224; ASN-3411; ASN-3465 AND
RP   ASN-3895.
RC   TISSUE=Liver;
RX   PubMed=19159218; DOI=10.1021/pr8008012;
RA   Chen R., Jiang X., Sun D., Han G., Wang F., Ye M., Wang L., Zou H.;
RT   "Glycoproteomics analysis of human liver tissue by combination of
RT   multiple enzyme digestion and hydrazide chemistry.";
RL   J. Proteome Res. 8:651-661(2009).
RN   [36]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-2004, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19608861; DOI=10.1126/science.1175371;
RA   Choudhary C., Kumar C., Gnad F., Nielsen M.L., Rehman M.,
RA   Walther T.C., Olsen J.V., Mann M.;
RT   "Lysine acetylation targets protein complexes and co-regulates major
RT   cellular functions.";
RL   Science 325:834-840(2009).
RN   [37]
RP   INVOLVEMENT IN LDLCQ4, AND VARIANT ILE-98.
RX   PubMed=20686565; DOI=10.1038/nature09270;
RA   Teslovich T.M., Musunuru K., Smith A.V., Edmondson A.C.,
RA   Stylianou I.M., Koseki M., Pirruccello J.P., Ripatti S., Chasman D.I.,
RA   Willer C.J., Johansen C.T., Fouchier S.W., Isaacs A., Peloso G.M.,
RA   Barbalic M., Ricketts S.L., Bis J.C., Aulchenko Y.S., Thorleifsson G.,
RA   Feitosa M.F., Chambers J., Orho-Melander M., Melander O., Johnson T.,
RA   Li X., Guo X., Li M., Shin Cho Y., Jin Go M., Jin Kim Y., Lee J.Y.,
RA   Park T., Kim K., Sim X., Twee-Hee Ong R., Croteau-Chonka D.C.,
RA   Lange L.A., Smith J.D., Song K., Hua Zhao J., Yuan X., Luan J.,
RA   Lamina C., Ziegler A., Zhang W., Zee R.Y., Wright A.F., Witteman J.C.,
RA   Wilson J.F., Willemsen G., Wichmann H.E., Whitfield J.B.,
RA   Waterworth D.M., Wareham N.J., Waeber G., Vollenweider P.,
RA   Voight B.F., Vitart V., Uitterlinden A.G., Uda M., Tuomilehto J.,
RA   Thompson J.R., Tanaka T., Surakka I., Stringham H.M., Spector T.D.,
RA   Soranzo N., Smit J.H., Sinisalo J., Silander K., Sijbrands E.J.,
RA   Scuteri A., Scott J., Schlessinger D., Sanna S., Salomaa V.,
RA   Saharinen J., Sabatti C., Ruokonen A., Rudan I., Rose L.M.,
RA   Roberts R., Rieder M., Psaty B.M., Pramstaller P.P., Pichler I.,
RA   Perola M., Penninx B.W., Pedersen N.L., Pattaro C., Parker A.N.,
RA   Pare G., Oostra B.A., O'Donnell C.J., Nieminen M.S., Nickerson D.A.,
RA   Montgomery G.W., Meitinger T., McPherson R., McCarthy M.I.,
RA   McArdle W., Masson D., Martin N.G., Marroni F., Mangino M.,
RA   Magnusson P.K., Lucas G., Luben R., Loos R.J., Lokki M.L., Lettre G.,
RA   Langenberg C., Launer L.J., Lakatta E.G., Laaksonen R., Kyvik K.O.,
RA   Kronenberg F., Konig I.R., Khaw K.T., Kaprio J., Kaplan L.M.,
RA   Johansson A., Jarvelin M.R., Janssens A.C., Ingelsson E., Igl W.,
RA   Kees Hovingh G., Hottenga J.J., Hofman A., Hicks A.A.,
RA   Hengstenberg C., Heid I.M., Hayward C., Havulinna A.S., Hastie N.D.,
RA   Harris T.B., Haritunians T., Hall A.S., Gyllensten U., Guiducci C.,
RA   Groop L.C., Gonzalez E., Gieger C., Freimer N.B., Ferrucci L.,
RA   Erdmann J., Elliott P., Ejebe K.G., Doring A., Dominiczak A.F.,
RA   Demissie S., Deloukas P., de Geus E.J., de Faire U., Crawford G.,
RA   Collins F.S., Chen Y.D., Caulfield M.J., Campbell H., Burtt N.P.,
RA   Bonnycastle L.L., Boomsma D.I., Boekholdt S.M., Bergman R.N.,
RA   Barroso I., Bandinelli S., Ballantyne C.M., Assimes T.L.,
RA   Quertermous T., Altshuler D., Seielstad M., Wong T.Y., Tai E.S.,
RA   Feranil A.B., Kuzawa C.W., Adair L.S., Taylor H.A. Jr., Borecki I.B.,
RA   Gabriel S.B., Wilson J.G., Holm H., Thorsteinsdottir U., Gudnason V.,
RA   Krauss R.M., Mohlke K.L., Ordovas J.M., Munroe P.B., Kooner J.S.,
RA   Tall A.R., Hegele R.A., Kastelein J.J., Schadt E.E., Rotter J.I.,
RA   Boerwinkle E., Strachan D.P., Mooser V., Stefansson K., Reilly M.P.,
RA   Samani N.J., Schunkert H., Cupples L.A., Sandhu M.S., Ridker P.M.,
RA   Rader D.J., van Duijn C.M., Peltonen L., Abecasis G.R., Boehnke M.,
RA   Kathiresan S.;
RT   "Biological, clinical and population relevance of 95 loci for blood
RT   lipids.";
RL   Nature 466:707-713(2010).
RN   [38]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [39]
RP   INVOLVEMENT IN FHBL1.
RX   PubMed=21981844; DOI=10.1016/j.jacl.2011.06.014;
RA   Gangloff A., Bergeron J., Couture P., Martins R., Hegele R.A.,
RA   Gagne C.;
RT   "A novel mutation of apolipoprotein B in a French Canadian family with
RT   homozygous hypobetalipoproteinemia.";
RL   J. Clin. Lipidol. 5:414-417(2011).
RN   [40]
RP   SUBCELLULAR LOCATION, AND INTERACTION WITH PCSK9.
RX   PubMed=22580899; DOI=10.1161/ATVBAHA.112.250043;
RA   Sun H., Samarghandi A., Zhang N., Yao Z., Xiong M., Teng B.B.;
RT   "Proprotein convertase subtilisin/kexin type 9 interacts with
RT   apolipoprotein B and prevents its intracellular degradation,
RT   irrespective of the low-density lipoprotein receptor.";
RL   Arterioscler. Thromb. Vasc. Biol. 32:1585-1595(2012).
RN   [41]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-3279; SER-4048 AND
RP   THR-4052, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [42]
RP   PHOSPHORYLATION AT SER-4048.
RX   PubMed=26091039; DOI=10.1016/j.cell.2015.05.028;
RA   Tagliabracci V.S., Wiley S.E., Guo X., Kinch L.N., Durrant E., Wen J.,
RA   Xiao J., Cui J., Nguyen K.B., Engel J.L., Coon J.J., Grishin N.,
RA   Pinna L.A., Pagliarini D.J., Dixon J.E.;
RT   "A single kinase generates the majority of the secreted
RT   phosphoproteome.";
RL   Cell 161:1619-1632(2015).
RN   [43]
RP   INTERACTION WITH MTTP, AND SUBCELLULAR LOCATION.
RX   PubMed=26224785; DOI=10.1161/CIRCGENETICS.115.001106;
RA   Walsh M.T., Iqbal J., Josekutty J., Soh J., Di Leo E., Oezaydin E.,
RA   Guenduez M., Tarugi P., Hussain M.M.;
RT   "A novel abetalipoproteinemia missense mutation highlights the
RT   importance of N-Terminal beta-barrel in microsomal triglyceride
RT   transfer protein function.";
RL   Circ. Cardiovasc. Genet. 8:677-687(2015).
RN   [44]
RP   VARIANT ASN-4338.
RX   PubMed=1979313; DOI=10.1007/BF00205183;
RA   Navajas M., Laurent A.-M., Moreel J.-F., Ragab A., Cambou J.-P.,
RA   Cunny G., Cambien F., Roizes G.;
RT   "Detection by denaturing gradient gel electrophoresis of a new
RT   polymorphism in the apolipoprotein B gene.";
RL   Hum. Genet. 86:91-93(1990).
RN   [45]
RP   VARIANT FDB GLN-3527.
RX   PubMed=2563166; DOI=10.1073/pnas.86.2.587;
RA   Soria L.F., Ludwig E.H., Clarke H.R.G., Vega G.L., Grundy S.M.,
RA   McCarthy B.J.;
RT   "Association between a specific apolipoprotein B mutation and familial
RT   defective apolipoprotein B-100.";
RL   Proc. Natl. Acad. Sci. U.S.A. 86:587-591(1989).
RN   [46]
RP   VARIANT LEU-2739.
RX   PubMed=2216805; DOI=10.1093/nar/18.19.5922-a;
RA   Huang L.-S., Gavish D., Breslow J.L.;
RT   "Sequence polymorphism in the human apoB gene at position 8344.";
RL   Nucleic Acids Res. 18:5922-5922(1990).
RN   [47]
RP   VARIANT FDB CYS-3558.
RX   PubMed=7883971; DOI=10.1172/JCI117772;
RA   Pullinger C.R., Hennessy L.K., Chatterton J.E., Liu W., Love J.A.,
RA   Mendel C.M., Frost P.H., Malloy M.J., Schumaker V.N., Kane J.P.;
RT   "Familial ligand-defective apolipoprotein B. Identification of a new
RT   mutation that decreases LDL receptor binding affinity.";
RL   J. Clin. Invest. 95:1225-1234(1995).
RN   [48]
RP   VARIANTS LEU-1437; SER-1914; LYS-2566; THR-3121; ALA-3945; MET-4128
RP   AND THR-4481.
RX   PubMed=8889592;
RX   DOI=10.1002/(SICI)1098-1004(1996)8:3<282::AID-HUMU16>3.3.CO;2-Y;
RA   Poirier O., Ricard S., Behague I., Souriau C., Evans A.E.,
RA   Arveiler D., Marques-Vidal P., Luc G., Roizes G., Cambien F.;
RT   "Detection of new variants in the apolipoprotein B (Apo B) gene by
RT   PCR-SSCP.";
RL   Hum. Mutat. 8:282-285(1996).
RN   [49]
RP   VARIANTS FDB GLN-3527 AND CYS-3558.
RX   PubMed=9259199;
RX   DOI=10.1002/(SICI)1098-1004(1997)10:2<160::AID-HUMU8>3.0.CO;2-O;
RA   Rabes J.P., Varret M., Saint-Jore B., Erlich D., Jondeau G.,
RA   Krempf M., Giraudet P., Junien C., Boileau C.;
RT   "Familial ligand-defective apolipoprotein B-100: simultaneous
RT   detection of the Arg3500-->Gln and Arg3531-->Cys mutations in a French
RT   population.";
RL   Hum. Mutat. 10:160-163(1997).
RN   [50]
RP   VARIANTS SER-1914; ARG-1923; LEU-2739; HIS-3319; LYS-3427; GLU-3432
RP   AND ILE-3921.
RX   PubMed=9490296; DOI=10.1007/s004390050651;
RA   Leren T.P., Bakken K.S., Hoel V., Hjermann I., Berg K.;
RT   "Screening for mutations of the apolipoprotein B gene causing
RT   hypocholesterolemia.";
RL   Hum. Genet. 102:44-49(1998).
RN   [51]
RP   VARIANT FHBL1 TRP-490, VARIANT ILE-98, CHARACTERIZATION OF VARIANT
RP   TRP-490, AND MUTAGENESIS OF ASP-483 AND ARG-490.
RX   PubMed=12551903; DOI=10.1074/jbc.M300235200;
RA   Burnett J.R., Shan J., Miskie B.A., Whitfield A.J., Yuan J., Tran K.,
RA   McKnight C.J., Hegele R.A., Yao Z.;
RT   "A novel nontruncating APOB gene mutation, R463W, causes familial
RT   hypobetalipoproteinemia.";
RL   J. Biol. Chem. 278:13442-13452(2003).
RN   [52]
RP   VARIANT HIS-1128.
RX   PubMed=14732481;
RA   Lancellotti S., Di Leo E., Penacchioni J.Y., Balli F., Viola L.,
RA   Bertolini S., Calandra S., Tarugi P.;
RT   "Hypobetalipoproteinemia with an apparently recessive inheritance due
RT   to a 'de novo' mutation of apolipoprotein B.";
RL   Biochim. Biophys. Acta 1688:61-67(2004).
RN   [53]
RP   VARIANT [LARGE SCALE ANALYSIS] CYS-2564.
RX   PubMed=16959974; DOI=10.1126/science.1133427;
RA   Sjoeblom T., Jones S., Wood L.D., Parsons D.W., Lin J., Barber T.D.,
RA   Mandelker D., Leary R.J., Ptak J., Silliman N., Szabo S.,
RA   Buckhaults P., Farrell C., Meeh P., Markowitz S.D., Willis J.,
RA   Dawson D., Willson J.K.V., Gazdar A.F., Hartigan J., Wu L., Liu C.,
RA   Parmigiani G., Park B.H., Bachman K.E., Papadopoulos N.,
RA   Vogelstein B., Kinzler K.W., Velculescu V.E.;
RT   "The consensus coding sequences of human breast and colorectal
RT   cancers.";
RL   Science 314:268-274(2006).
RN   [54]
RP   VARIANT FDB GLN-3527.
RX   PubMed=21382890; DOI=10.1161/CIRCULATIONAHA.110.979450;
RA   van der Graaf A., Avis H.J., Kusters D.M., Vissers M.N., Hutten B.A.,
RA   Defesche J.C., Huijgen R., Fouchier S.W., Wijburg F.A.,
RA   Kastelein J.J., Wiegman A.;
RT   "Molecular basis of autosomal dominant hypercholesterolemia:
RT   assessment in a large cohort of hypercholesterolemic children.";
RL   Circulation 123:1167-1173(2011).
RN   [55]
RP   VARIANTS GLU-1218; ASP-1670; ASN-2037; CYS-2564 AND LYS-2566, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY.
RX   PubMed=22028381; DOI=10.1093/jmcb/mjr024;
RA   Su Z.D., Sun L., Yu D.X., Li R.X., Li H.X., Yu Z.J., Sheng Q.H.,
RA   Lin X., Zeng R., Wu J.R.;
RT   "Quantitative detection of single amino acid polymorphisms by targeted
RT   proteomics.";
RL   J. Mol. Cell Biol. 3:309-315(2011).
RN   [56]
RP   VARIANTS 12-LEU--LEU-14 DEL; ILE-98; VAL-618; ILE-730; THR-1613;
RP   ARG-1923; LYS-2566; LEU-2739; GLN-3638; LEU-3835; LYS-4181; THR-4270;
RP   VAL-4314; ASN-4338; THR-4481 AND VAL-4482.
RX   PubMed=22095935; DOI=10.1002/humu.21660;
RA   Huijgen R., Sjouke B., Vis K., de Randamie J.S., Defesche J.C.,
RA   Kastelein J.J., Hovingh G.K., Fouchier S.W.;
RT   "Genetic variation in APOB, PCSK9, and ANGPTL3 in carriers of
RT   pathogenic autosomal dominant hypercholesterolemic mutations with
RT   unexpected low LDL-Cl Levels.";
RL   Hum. Mutat. 33:448-455(2012).
RN   [57]
RP   VARIANT FHBL1 LEU-952, VARIANT THR-251, CHARACTERIZATION OF VARIANT
RP   FHBL1 LEU-952, CHARACTERIZATION OF VARIANT THR-251, AND INTERACTION
RP   WITH MTTP.
RX   PubMed=27206948; DOI=10.1016/j.jacl.2016.01.006;
RA   Miller S.A., Hooper A.J., Mantiri G.A., Marais D., Tanyanyiwa D.M.,
RA   McKnight J., Burnett J.R.;
RT   "Novel APOB missense variants, A224T and V925L, in a black South
RT   African woman with marked hypocholesterolemia.";
RL   J. Clin. Lipidol. 10:604-609(2016).
CC   -!- FUNCTION: Apolipoprotein B is a major protein constituent of
CC       chylomicrons (apo B-48), LDL (apo B-100) and VLDL (apo B-100). Apo
CC       B-100 functions as a recognition signal for the cellular binding
CC       and internalization of LDL particles by the apoB/E receptor.
CC   -!- SUBUNIT: Interacts with PCSK9 (PubMed:22580899). Interacts with
CC       MTTP (PubMed:26224785, PubMed:27206948).
CC       {ECO:0000269|PubMed:22580899, ECO:0000269|PubMed:26224785,
CC       ECO:0000269|PubMed:27206948}.
CC   -!- INTERACTION:
CC       P29991:- (xeno); NbExp=3; IntAct=EBI-3926040, EBI-8826488;
CC       P01130:LDLR; NbExp=4; IntAct=EBI-3926040, EBI-988319;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:22580899}.
CC       Secreted {ECO:0000269|PubMed:22580899,
CC       ECO:0000269|PubMed:26224785}.
CC   -!- INDUCTION: Up-regulated in response to enterovirus 71 (EV71)
CC       infection (at protein level). {ECO:0000269|PubMed:16548883}.
CC   -!- PTM: Palmitoylated; structural requirement for proper assembly of
CC       the hydrophobic core of the lipoprotein particle.
CC       {ECO:0000269|PubMed:10679026}.
CC   -!- RNA EDITING: Modified_positions=2180; Note=The stop codon (UAA) at
CC       position 2180 is created by RNA editing. Apo B-48, derived from
CC       the fully edited RNA, is produced only in the intestine and is
CC       found in chylomicrons. Apo B-48 is a shortened form of apo B-100
CC       which lacks the LDL-receptor region. The unedited version (apo B-
CC       100) is produced by the liver and is found in the VLDL and LDL.;
CC   -!- POLYMORPHISM: Genetic variations in APOB define the low density
CC       lipoprotein cholesterol level quantitative trait locus 4 (LDLCQ4)
CC       [MIM:107730].
CC   -!- DISEASE: Hypobetalipoproteinemia, familial, 1 (FHBL1)
CC       [MIM:615558]: A disorder of lipid metabolism characterized by less
CC       than 5th percentile age- and sex-specific levels of low density
CC       lipoproteins, and dietary fat malabsorption. Clinical presentation
CC       may vary from no symptoms to severe gastrointestinal and
CC       neurological dysfunction similar to abetalipoproteinemia.
CC       {ECO:0000269|PubMed:12551903, ECO:0000269|PubMed:21981844,
CC       ECO:0000269|PubMed:27206948}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry. Most cases
CC       of FHBL1 result from nonsense mutations in the APOB gene that lead
CC       to a premature stop codon, which generate prematurely truncated
CC       apo B protein products (PubMed:21981844).
CC       {ECO:0000269|PubMed:21981844}.
CC   -!- DISEASE: Familial ligand-defective apolipoprotein B-100 (FDB)
CC       [MIM:144010]: Dominantly inherited disorder of lipoprotein
CC       metabolism leading to hypercholesterolemia and increased proneness
CC       to coronary artery disease (CAD). The plasma cholesterol levels
CC       are dramatically elevated due to impaired clearance of LDL
CC       particles by defective APOB/E receptors.
CC       {ECO:0000269|PubMed:21382890, ECO:0000269|PubMed:2563166,
CC       ECO:0000269|PubMed:7883971, ECO:0000269|PubMed:9259199}. Note=The
CC       disease is caused by mutations affecting the gene represented in
CC       this entry.
CC   -!- DISEASE: Note=Defects in APOB associated with defects in other
CC       genes (polygenic) can contribute to hypocholesterolemia.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAA51752.1; Type=Frameshift; Positions=942, 951, 1139, 1165, 1164, 1371, 1385; Evidence={ECO:0000305};
CC   -!- WEB RESOURCE: Name=SHMPD; Note=The Singapore human mutation and
CC       polymorphism database;
CC       URL="http://shmpd.bii.a-star.edu.sg/gene.php?genestart=A&genename=APOB";
CC   -!- WEB RESOURCE: Name=Wikipedia; Note=Apolipoprotein B entry;
CC       URL="https://en.wikipedia.org/wiki/Apolipoprotein_B";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; X04506; CAA28191.1; -; mRNA.
DR   EMBL; M19828; AAB00481.1; -; Genomic_DNA.
DR   EMBL; M19808; AAB00481.1; JOINED; Genomic_DNA.
DR   EMBL; M19809; AAB00481.1; JOINED; Genomic_DNA.
DR   EMBL; M19810; AAB00481.1; JOINED; Genomic_DNA.
DR   EMBL; M19811; AAB00481.1; JOINED; Genomic_DNA.
DR   EMBL; M19812; AAB00481.1; JOINED; Genomic_DNA.
DR   EMBL; M19813; AAB00481.1; JOINED; Genomic_DNA.
DR   EMBL; M19815; AAB00481.1; JOINED; Genomic_DNA.
DR   EMBL; M19816; AAB00481.1; JOINED; Genomic_DNA.
DR   EMBL; M19818; AAB00481.1; JOINED; Genomic_DNA.
DR   EMBL; M19820; AAB00481.1; JOINED; Genomic_DNA.
DR   EMBL; M19821; AAB00481.1; JOINED; Genomic_DNA.
DR   EMBL; M19823; AAB00481.1; JOINED; Genomic_DNA.
DR   EMBL; M19824; AAB00481.1; JOINED; Genomic_DNA.
DR   EMBL; M19825; AAB00481.1; JOINED; Genomic_DNA.
DR   EMBL; M19827; AAB00481.1; JOINED; Genomic_DNA.
DR   EMBL; J02610; AAA35549.1; -; mRNA.
DR   EMBL; M14162; AAB04636.1; -; mRNA.
DR   EMBL; M15053; AAB60718.1; -; Genomic_DNA.
DR   EMBL; X04714; CAA28420.1; -; mRNA.
DR   EMBL; AY324608; AAP72970.1; -; Genomic_DNA.
DR   EMBL; AC010872; AAX88848.1; -; Genomic_DNA.
DR   EMBL; AC115619; AAX93246.1; -; Genomic_DNA.
DR   EMBL; M14081; AAA51752.1; ALT_FRAME; mRNA.
DR   EMBL; M12681; AAA51753.1; -; mRNA.
DR   EMBL; M12480; AAA51751.1; -; mRNA.
DR   EMBL; K03175; AAA51759.1; -; mRNA.
DR   EMBL; M15421; AAA51758.1; -; mRNA.
DR   EMBL; M17367; AAA51741.1; -; mRNA.
DR   EMBL; M31030; AAA51756.1; -; mRNA.
DR   EMBL; X03325; CAA27044.1; -; mRNA.
DR   EMBL; X03326; CAA27045.1; -; mRNA.
DR   EMBL; M17779; AAA51755.1; -; mRNA.
DR   EMBL; M19734; AAA35544.1; -; mRNA.
DR   EMBL; M18471; AAA35541.1; -; mRNA.
DR   EMBL; X03045; CAA26850.1; -; mRNA.
DR   EMBL; M10374; AAA51750.1; -; mRNA.
DR   EMBL; M12413; AAA51742.1; -; mRNA.
DR   EMBL; M36676; AAA35548.1; -; mRNA.
DR   CCDS; CCDS1703.1; -.
DR   PIR; A27850; LPHUB.
DR   RefSeq; NP_000375.2; NM_000384.2.
DR   UniGene; Hs.120759; -.
DR   ProteinModelPortal; P04114; -.
DR   SMR; P04114; -.
DR   BioGrid; 106835; 64.
DR   DIP; DIP-44767N; -.
DR   IntAct; P04114; 30.
DR   MINT; MINT-1506918; -.
DR   STRING; 9606.ENSP00000233242; -.
DR   BindingDB; P04114; -.
DR   ChEMBL; CHEMBL4549; -.
DR   iPTMnet; P04114; -.
DR   PhosphoSitePlus; P04114; -.
DR   SwissPalm; P04114; -.
DR   UniCarbKB; P04114; -.
DR   BioMuta; APOB; -.
DR   DMDM; 300669605; -.
DR   EPD; P04114; -.
DR   MaxQB; P04114; -.
DR   PaxDb; P04114; -.
DR   PeptideAtlas; P04114; -.
DR   PRIDE; P04114; -.
DR   Ensembl; ENST00000233242; ENSP00000233242; ENSG00000084674.
DR   GeneID; 338; -.
DR   KEGG; hsa:338; -.
DR   UCSC; uc002red.3; human.
DR   CTD; 338; -.
DR   DisGeNET; 338; -.
DR   GeneCards; APOB; -.
DR   GeneReviews; APOB; -.
DR   H-InvDB; HIX0024005; -.
DR   HGNC; HGNC:603; APOB.
DR   HPA; CAB016070; -.
DR   HPA; HPA049793; -.
DR   MalaCards; APOB; -.
DR   MIM; 107730; gene+phenotype.
DR   MIM; 144010; phenotype.
DR   MIM; 615558; phenotype.
DR   neXtProt; NX_P04114; -.
DR   Orphanet; 426; Familial hypobetalipoproteinemia.
DR   Orphanet; 406; Heterozygous familial hypercholesterolemia.
DR   Orphanet; 391665; Homozygous familial hypercholesterolemia.
DR   PharmGKB; PA50; -.
DR   eggNOG; KOG4338; Eukaryota.
DR   eggNOG; ENOG411104F; LUCA.
DR   HOVERGEN; HBG050546; -.
DR   InParanoid; P04114; -.
DR   KO; K14462; -.
DR   OrthoDB; EOG091G000G; -.
DR   PhylomeDB; P04114; -.
DR   TreeFam; TF331316; -.
DR   Reactome; R-HSA-171052; LDL-mediated lipid transport.
DR   Reactome; R-HSA-174800; Chylomicron-mediated lipid transport.
DR   Reactome; R-HSA-202733; Cell surface interactions at the vascular wall.
DR   Reactome; R-HSA-3000471; Scavenging by Class B Receptors.
DR   Reactome; R-HSA-3000480; Scavenging by Class A Receptors.
DR   Reactome; R-HSA-3000484; Scavenging by Class F Receptors.
DR   Reactome; R-HSA-3000497; Scavenging by Class H Receptors.
DR   Reactome; R-HSA-432142; Platelet sensitization by LDL.
DR   Reactome; R-HSA-5686938; Regulation of TLR by endogenous ligand.
DR   Reactome; R-HSA-8855121; VLDL interactions.
DR   Reactome; R-HSA-8856825; Cargo recognition for clathrin-mediated endocytosis.
DR   Reactome; R-HSA-8856828; Clathrin-mediated endocytosis.
DR   Reactome; R-HSA-8866423; VLDL biosynthesis.
DR   Reactome; R-HSA-975634; Retinoid metabolism and transport.
DR   SIGNOR; P04114; -.
DR   ChiTaRS; APOB; human.
DR   GeneWiki; Apolipoprotein_B; -.
DR   GenomeRNAi; 338; -.
DR   PRO; PR:P04114; -.
DR   Proteomes; UP000005640; Chromosome 2.
DR   Bgee; ENSG00000084674; -.
DR   ExpressionAtlas; P04114; baseline and differential.
DR   Genevisible; P04114; HS.
DR   GO; GO:0042627; C:chylomicron; IDA:BHF-UCL.
DR   GO; GO:0034360; C:chylomicron remnant; TAS:BHF-UCL.
DR   GO; GO:0030669; C:clathrin-coated endocytic vesicle membrane; TAS:Reactome.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0005829; C:cytosol; IDA:HPA.
DR   GO; GO:0005769; C:early endosome; TAS:Reactome.
DR   GO; GO:0071682; C:endocytic vesicle lumen; TAS:Reactome.
DR   GO; GO:0070971; C:endoplasmic reticulum exit site; IDA:UniProtKB.
DR   GO; GO:0005788; C:endoplasmic reticulum lumen; TAS:Reactome.
DR   GO; GO:0005789; C:endoplasmic reticulum membrane; TAS:Reactome.
DR   GO; GO:0031904; C:endosome lumen; TAS:Reactome.
DR   GO; GO:0010008; C:endosome membrane; TAS:Reactome.
DR   GO; GO:0070062; C:extracellular exosome; IDA:UniProtKB.
DR   GO; GO:0005576; C:extracellular region; TAS:Reactome.
DR   GO; GO:0005615; C:extracellular space; ISS:BHF-UCL.
DR   GO; GO:0034363; C:intermediate-density lipoprotein particle; IDA:BHF-UCL.
DR   GO; GO:0043231; C:intracellular membrane-bounded organelle; IDA:HPA.
DR   GO; GO:0034362; C:low-density lipoprotein particle; IDA:BHF-UCL.
DR   GO; GO:0043202; C:lysosomal lumen; TAS:Reactome.
DR   GO; GO:0034359; C:mature chylomicron; IDA:BHF-UCL.
DR   GO; GO:0043025; C:neuronal cell body; IDA:MGI.
DR   GO; GO:0005886; C:plasma membrane; TAS:Reactome.
DR   GO; GO:0005790; C:smooth endoplasmic reticulum; TAS:Reactome.
DR   GO; GO:0034361; C:very-low-density lipoprotein particle; IDA:BHF-UCL.
DR   GO; GO:0017127; F:cholesterol transporter activity; IMP:BHF-UCL.
DR   GO; GO:0008201; F:heparin binding; IDA:BHF-UCL.
DR   GO; GO:0035473; F:lipase binding; IPI:BHF-UCL.
DR   GO; GO:0050750; F:low-density lipoprotein particle receptor binding; IMP:BHF-UCL.
DR   GO; GO:0005543; F:phospholipid binding; IDA:BHF-UCL.
DR   GO; GO:0048844; P:artery morphogenesis; IEA:Ensembl.
DR   GO; GO:0044257; P:cellular protein catabolic process; TAS:Reactome.
DR   GO; GO:0071379; P:cellular response to prostaglandin stimulus; IEA:Ensembl.
DR   GO; GO:0071356; P:cellular response to tumor necrosis factor; IEA:Ensembl.
DR   GO; GO:0033344; P:cholesterol efflux; IEA:Ensembl.
DR   GO; GO:0042632; P:cholesterol homeostasis; IMP:BHF-UCL.
DR   GO; GO:0008203; P:cholesterol metabolic process; IMP:BHF-UCL.
DR   GO; GO:0030301; P:cholesterol transport; IMP:BHF-UCL.
DR   GO; GO:0009566; P:fertilization; IEA:Ensembl.
DR   GO; GO:0030317; P:flagellated sperm motility; IEA:Ensembl.
DR   GO; GO:0001701; P:in utero embryonic development; IEA:Ensembl.
DR   GO; GO:0050900; P:leukocyte migration; TAS:Reactome.
DR   GO; GO:0042158; P:lipoprotein biosynthetic process; TAS:Reactome.
DR   GO; GO:0042159; P:lipoprotein catabolic process; TAS:Reactome.
DR   GO; GO:0042157; P:lipoprotein metabolic process; TAS:Reactome.
DR   GO; GO:0042953; P:lipoprotein transport; IEA:Ensembl.
DR   GO; GO:0034383; P:low-density lipoprotein particle clearance; IMP:BHF-UCL.
DR   GO; GO:0034374; P:low-density lipoprotein particle remodeling; IMP:BHF-UCL.
DR   GO; GO:0061024; P:membrane organization; TAS:Reactome.
DR   GO; GO:0007399; P:nervous system development; IEA:Ensembl.
DR   GO; GO:0010886; P:positive regulation of cholesterol storage; IDA:BHF-UCL.
DR   GO; GO:0010628; P:positive regulation of gene expression; IEA:Ensembl.
DR   GO; GO:0010884; P:positive regulation of lipid storage; IDA:BHF-UCL.
DR   GO; GO:0010744; P:positive regulation of macrophage derived foam cell differentiation; IDA:BHF-UCL.
DR   GO; GO:0009791; P:post-embryonic development; IEA:Ensembl.
DR   GO; GO:0006898; P:receptor-mediated endocytosis; TAS:Reactome.
DR   GO; GO:0045540; P:regulation of cholesterol biosynthetic process; IEA:Ensembl.
DR   GO; GO:0009743; P:response to carbohydrate; IEA:Ensembl.
DR   GO; GO:0032355; P:response to estradiol; IEA:Ensembl.
DR   GO; GO:0032496; P:response to lipopolysaccharide; IEA:Ensembl.
DR   GO; GO:0010269; P:response to selenium ion; IEA:Ensembl.
DR   GO; GO:0009615; P:response to virus; IEP:UniProtKB.
DR   GO; GO:0001523; P:retinoid metabolic process; TAS:Reactome.
DR   GO; GO:0007283; P:spermatogenesis; IEA:Ensembl.
DR   GO; GO:0002224; P:toll-like receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0019433; P:triglyceride catabolic process; IEA:Ensembl.
DR   GO; GO:0006642; P:triglyceride mobilization; IEA:Ensembl.
DR   GO; GO:0034379; P:very-low-density lipoprotein particle assembly; IC:BHF-UCL.
DR   Gene3D; 2.20.50.20; -; 1.
DR   Gene3D; 2.30.230.10; -; 1.
DR   InterPro; IPR022176; ApoB100_C.
DR   InterPro; IPR016024; ARM-type_fold.
DR   InterPro; IPR015819; Lipid_transp_b-sht_shell.
DR   InterPro; IPR001747; Lipid_transpt_N.
DR   InterPro; IPR009454; Lipid_transpt_open_b-sht.
DR   InterPro; IPR015816; Vitellinogen_b-sht_N.
DR   InterPro; IPR015255; Vitellinogen_open_b-sht.
DR   InterPro; IPR015817; Vitellinogen_open_b-sht_sub1.
DR   InterPro; IPR011030; Vitellinogen_superhlx.
DR   Pfam; PF12491; ApoB100_C; 1.
DR   Pfam; PF06448; DUF1081; 1.
DR   Pfam; PF09172; DUF1943; 1.
DR   Pfam; PF01347; Vitellogenin_N; 1.
DR   SMART; SM01169; DUF1943; 1.
DR   SMART; SM00638; LPD_N; 1.
DR   SUPFAM; SSF48371; SSF48371; 2.
DR   SUPFAM; SSF48431; SSF48431; 1.
DR   SUPFAM; SSF56968; SSF56968; 2.
DR   PROSITE; PS51211; VITELLOGENIN; 1.
PE   1: Evidence at protein level;
KW   Acetylation; Atherosclerosis; Cholesterol metabolism; Chylomicron;
KW   Complete proteome; Cytoplasm; Direct protein sequencing;
KW   Disease mutation; Disulfide bond; Glycoprotein; Heparin-binding; LDL;
KW   Lipid metabolism; Lipid transport; Lipoprotein; Palmitate;
KW   Phosphoprotein; Polymorphism; Reference proteome; RNA editing;
KW   Secreted; Signal; Steroid metabolism; Sterol metabolism; Transport;
KW   VLDL.
FT   SIGNAL        1     27
FT   CHAIN        28   4563       Apolipoprotein B-100.
FT                                /FTId=PRO_0000020750.
FT   CHAIN        28   2179       Apolipoprotein B-48.
FT                                /FTId=PRO_0000020751.
FT   DOMAIN       46    672       Vitellogenin. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00557}.
FT   REGION       32    126       Heparin-binding.
FT   REGION      232    306       Heparin-binding.
FT   REGION      902    959       Heparin-binding.
FT   REGION     2043   2178       Heparin-binding.
FT   REGION     3161   3236       Heparin-binding.
FT   REGION     3174   3184       Basic (possible receptor binding region).
FT   REGION     3373   3393       LDL receptor binding.
FT   REGION     3383   3516       Heparin-binding.
FT   REGION     3386   3394       Basic (possible receptor binding region).
FT   MOD_RES    2004   2004       N6-acetyllysine.
FT                                {ECO:0000244|PubMed:19608861}.
FT   MOD_RES    3279   3279       Phosphoserine.
FT                                {ECO:0000244|PubMed:24275569}.
FT   MOD_RES    4048   4048       Phosphoserine; by FAM20C.
FT                                {ECO:0000244|PubMed:24275569,
FT                                ECO:0000269|PubMed:26091039}.
FT   MOD_RES    4052   4052       Phosphothreonine.
FT                                {ECO:0000244|PubMed:24275569}.
FT   LIPID      1112   1112       S-palmitoyl cysteine.
FT                                {ECO:0000269|PubMed:10679026}.
FT   CARBOHYD     34     34       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    185    185       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000269|PubMed:19159218}.
FT   CARBOHYD    983    983       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD   1368   1368       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD   1377   1377       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD   1523   1523       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000269|PubMed:16335952,
FT                                ECO:0000269|PubMed:19159218}.
FT   CARBOHYD   2239   2239       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000269|PubMed:19159218}.
FT   CARBOHYD   2560   2560       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD   2779   2779       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000269|PubMed:19159218}.
FT   CARBOHYD   2982   2982       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000269|PubMed:16335952,
FT                                ECO:0000269|PubMed:19159218}.
FT   CARBOHYD   3101   3101       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000269|PubMed:19159218}.
FT   CARBOHYD   3224   3224       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000269|PubMed:19159218}.
FT   CARBOHYD   3336   3336       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD   3358   3358       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000269|PubMed:14760718}.
FT   CARBOHYD   3411   3411       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000269|PubMed:19159218}.
FT   CARBOHYD   3465   3465       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000269|PubMed:16335952,
FT                                ECO:0000269|PubMed:19159218}.
FT   CARBOHYD   3895   3895       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000269|PubMed:16335952,
FT                                ECO:0000269|PubMed:19159218}.
FT   CARBOHYD   4237   4237       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD   4431   4431       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   DISULFID     39     88       {ECO:0000255|PROSITE-ProRule:PRU00557,
FT                                ECO:0000269|PubMed:2115173}.
FT   DISULFID     78     97       {ECO:0000255|PROSITE-ProRule:PRU00557,
FT                                ECO:0000269|PubMed:2115173}.
FT   DISULFID    186    212       {ECO:0000255|PROSITE-ProRule:PRU00557,
FT                                ECO:0000269|PubMed:2115173}.
FT   DISULFID    245    261       {ECO:0000255|PROSITE-ProRule:PRU00557,
FT                                ECO:0000269|PubMed:2115173}.
FT   DISULFID    385    390       {ECO:0000255|PROSITE-ProRule:PRU00557,
FT                                ECO:0000269|PubMed:2115173}.
FT   DISULFID    478    513       {ECO:0000255|PROSITE-ProRule:PRU00557,
FT                                ECO:0000269|PubMed:2115173}.
FT   DISULFID    966    976       {ECO:0000255|PROSITE-ProRule:PRU00557,
FT                                ECO:0000269|PubMed:2115173}.
FT   DISULFID   3194   3324       {ECO:0000255|PROSITE-ProRule:PRU00557,
FT                                ECO:0000269|PubMed:2115173}.
FT   VARIANT      12     14       Missing. {ECO:0000269|PubMed:22095935}.
FT                                /FTId=VAR_067277.
FT   VARIANT      98     98       T -> I (polymorphism that influences
FT                                plasma concentrations of low density
FT                                lipoprotein cholesterol;
FT                                dbSNP:rs1367117).
FT                                {ECO:0000269|PubMed:12551903,
FT                                ECO:0000269|PubMed:20686565,
FT                                ECO:0000269|PubMed:2115173,
FT                                ECO:0000269|PubMed:22095935,
FT                                ECO:0000269|PubMed:3461454,
FT                                ECO:0000269|PubMed:3759943}.
FT                                /FTId=VAR_016184.
FT   VARIANT     103    103       Y -> H (in dbSNP:rs9282603).
FT                                /FTId=VAR_022036.
FT   VARIANT     145    145       P -> S (in dbSNP:rs6752026).
FT                                /FTId=VAR_022037.
FT   VARIANT     194    194       T -> M (in dbSNP:rs13306198).
FT                                /FTId=VAR_056737.
FT   VARIANT     251    251       A -> T (polymorphism; does not affect
FT                                plasma lipid levels; dbSNP:rs61741625).
FT                                {ECO:0000269|PubMed:27206948}.
FT                                /FTId=VAR_076538.
FT   VARIANT     273    273       K -> N (in dbSNP:rs1126419).
FT                                {ECO:0000269|PubMed:3763409}.
FT                                /FTId=VAR_019827.
FT   VARIANT     408    408       I -> T (in dbSNP:rs12714225).
FT                                /FTId=VAR_029341.
FT   VARIANT     490    490       R -> W (in FHBL1; reduced protein
FT                                secretion).
FT                                {ECO:0000269|PubMed:12551903}.
FT                                /FTId=VAR_022610.
FT   VARIANT     554    554       P -> L (in dbSNP:rs12714214).
FT                                /FTId=VAR_020135.
FT   VARIANT     618    618       A -> V (in dbSNP:rs679899).
FT                                {ECO:0000269|PubMed:22095935,
FT                                ECO:0000269|PubMed:3030729,
FT                                ECO:0000269|PubMed:3759943}.
FT                                /FTId=VAR_019828.
FT   VARIANT     730    730       V -> I (in dbSNP:rs12691202).
FT                                {ECO:0000269|PubMed:22095935}.
FT                                /FTId=VAR_020136.
FT   VARIANT     733    733       V -> I (in dbSNP:rs1800476).
FT                                /FTId=VAR_016185.
FT   VARIANT     741    741       T -> N (in dbSNP:rs12714192).
FT                                /FTId=VAR_020137.
FT   VARIANT     877    877       P -> L (in dbSNP:rs12714097).
FT                                /FTId=VAR_029342.
FT   VARIANT     952    952       V -> L (in FHBL1; unknown pathological
FT                                significance; does not affect interaction
FT                                with MTTP).
FT                                {ECO:0000269|PubMed:27206948}.
FT                                /FTId=VAR_076539.
FT   VARIANT     955    955       P -> S (in dbSNP:rs13306206).
FT                                /FTId=VAR_056738.
FT   VARIANT    1086   1086       G -> S (in dbSNP:rs12720801).
FT                                /FTId=VAR_029343.
FT   VARIANT    1113   1113       D -> H (in dbSNP:rs12713844).
FT                                /FTId=VAR_029344.
FT   VARIANT    1128   1128       R -> H (in dbSNP:rs12713843).
FT                                {ECO:0000269|PubMed:14732481}.
FT                                /FTId=VAR_022611.
FT   VARIANT    1218   1218       Q -> E (polymorphism; confirmed at
FT                                protein level; dbSNP:rs1041956).
FT                                {ECO:0000269|PubMed:22028381,
FT                                ECO:0000269|PubMed:3763409}.
FT                                /FTId=VAR_019829.
FT   VARIANT    1388   1388       R -> H (in dbSNP:rs13306187).
FT                                /FTId=VAR_029345.
FT   VARIANT    1422   1422       Y -> C (in dbSNP:rs568413).
FT                                {ECO:0000269|PubMed:2883086,
FT                                ECO:0000269|PubMed:3030729,
FT                                ECO:0000269|PubMed:3461454,
FT                                ECO:0000269|PubMed:3464946,
FT                                ECO:0000269|PubMed:3652907,
FT                                ECO:0000269|PubMed:3759943,
FT                                ECO:0000269|PubMed:3763409,
FT                                ECO:0000269|Ref.6}.
FT                                /FTId=VAR_061558.
FT   VARIANT    1437   1437       F -> L (in dbSNP:rs1801697).
FT                                {ECO:0000269|PubMed:8889592}.
FT                                /FTId=VAR_005016.
FT   VARIANT    1613   1613       S -> T. {ECO:0000269|PubMed:22095935}.
FT                                /FTId=VAR_067278.
FT   VARIANT    1670   1670       E -> D (polymorphism; confirmed at
FT                                protein level).
FT                                {ECO:0000269|PubMed:22028381,
FT                                ECO:0000269|PubMed:3461454}.
FT                                /FTId=VAR_068911.
FT   VARIANT    1914   1914       N -> S (in dbSNP:rs1801699).
FT                                {ECO:0000269|PubMed:8889592,
FT                                ECO:0000269|PubMed:9490296}.
FT                                /FTId=VAR_005017.
FT   VARIANT    1923   1923       H -> R (in dbSNP:rs533617).
FT                                {ECO:0000269|PubMed:22095935,
FT                                ECO:0000269|PubMed:9490296}.
FT                                /FTId=VAR_005018.
FT   VARIANT    2037   2037       I -> N (polymorphism; confirmed at
FT                                protein level).
FT                                {ECO:0000269|PubMed:22028381,
FT                                ECO:0000269|PubMed:3464946}.
FT                                /FTId=VAR_068912.
FT   VARIANT    2092   2092       L -> V (in dbSNP:rs1041960).
FT                                {ECO:0000269|PubMed:3763409}.
FT                                /FTId=VAR_019830.
FT   VARIANT    2299   2299       D -> H (in dbSNP:rs12713681).
FT                                /FTId=VAR_029346.
FT   VARIANT    2313   2313       I -> V (in dbSNP:rs584542).
FT                                {ECO:0000269|PubMed:2883086,
FT                                ECO:0000269|PubMed:3030729,
FT                                ECO:0000269|PubMed:3464946,
FT                                ECO:0000269|PubMed:3652907,
FT                                ECO:0000269|PubMed:3676265,
FT                                ECO:0000269|PubMed:3759943,
FT                                ECO:0000269|PubMed:3763409,
FT                                ECO:0000269|Ref.6}.
FT                                /FTId=VAR_059582.
FT   VARIANT    2365   2365       A -> T (in dbSNP:rs1041971).
FT                                {ECO:0000269|PubMed:3763409}.
FT                                /FTId=VAR_019831.
FT   VARIANT    2456   2456       A -> D (in dbSNP:rs12713675).
FT                                /FTId=VAR_020138.
FT   VARIANT    2564   2564       F -> C (in a colorectal cancer sample;
FT                                somatic mutation; confirmed at protein
FT                                level). {ECO:0000269|PubMed:16959974,
FT                                ECO:0000269|PubMed:22028381}.
FT                                /FTId=VAR_035795.
FT   VARIANT    2566   2566       E -> K (polymorphism; confirmed at
FT                                protein level; dbSNP:rs1801696).
FT                                {ECO:0000269|PubMed:22028381,
FT                                ECO:0000269|PubMed:22095935,
FT                                ECO:0000269|PubMed:8889592}.
FT                                /FTId=VAR_005019.
FT   VARIANT    2680   2680       L -> Q (in dbSNP:rs1042013).
FT                                {ECO:0000269|PubMed:3763409}.
FT                                /FTId=VAR_019832.
FT   VARIANT    2739   2739       P -> L (in dbSNP:rs676210).
FT                                {ECO:0000269|PubMed:22095935,
FT                                ECO:0000269|PubMed:2216805,
FT                                ECO:0000269|PubMed:9490296}.
FT                                /FTId=VAR_005020.
FT   VARIANT    2785   2785       N -> H (in dbSNP:rs2163204).
FT                                /FTId=VAR_022038.
FT   VARIANT    3121   3121       A -> T (in dbSNP:rs1801694).
FT                                {ECO:0000269|PubMed:8889592}.
FT                                /FTId=VAR_005021.
FT   VARIANT    3182   3182       H -> N (in dbSNP:rs12720848).
FT                                /FTId=VAR_029347.
FT   VARIANT    3279   3279       S -> G (in dbSNP:rs12720854).
FT                                /FTId=VAR_029348.
FT   VARIANT    3294   3294       S -> P (in dbSNP:rs12720855).
FT                                /FTId=VAR_020139.
FT   VARIANT    3319   3319       D -> H. {ECO:0000269|PubMed:2883086,
FT                                ECO:0000269|PubMed:2994225,
FT                                ECO:0000269|PubMed:3030729,
FT                                ECO:0000269|PubMed:3464946,
FT                                ECO:0000269|PubMed:3652907,
FT                                ECO:0000269|PubMed:3759943,
FT                                ECO:0000269|PubMed:3763409,
FT                                ECO:0000269|PubMed:9490296}.
FT                                /FTId=VAR_005022.
FT   VARIANT    3427   3427       T -> K. {ECO:0000269|PubMed:2883086,
FT                                ECO:0000269|PubMed:2994225,
FT                                ECO:0000269|PubMed:3030729,
FT                                ECO:0000269|PubMed:3464946,
FT                                ECO:0000269|PubMed:3652907,
FT                                ECO:0000269|PubMed:3759943,
FT                                ECO:0000269|PubMed:3763409,
FT                                ECO:0000269|PubMed:9490296}.
FT                                /FTId=VAR_005023.
FT   VARIANT    3432   3432       Q -> E (in dbSNP:rs1042023).
FT                                {ECO:0000269|PubMed:2883086,
FT                                ECO:0000269|PubMed:2994225,
FT                                ECO:0000269|PubMed:3030729,
FT                                ECO:0000269|PubMed:3464946,
FT                                ECO:0000269|PubMed:3652907,
FT                                ECO:0000269|PubMed:3759943,
FT                                ECO:0000269|PubMed:3763409,
FT                                ECO:0000269|PubMed:9490296}.
FT                                /FTId=VAR_005024.
FT   VARIANT    3527   3527       R -> Q (in FDB; dbSNP:rs5742904).
FT                                {ECO:0000269|PubMed:21382890,
FT                                ECO:0000269|PubMed:2563166,
FT                                ECO:0000269|PubMed:9259199}.
FT                                /FTId=VAR_005025.
FT   VARIANT    3558   3558       R -> C (in FDB; dbSNP:rs12713559).
FT                                {ECO:0000269|PubMed:7883971,
FT                                ECO:0000269|PubMed:9259199}.
FT                                /FTId=VAR_005026.
FT   VARIANT    3638   3638       R -> Q (in dbSNP:rs1801701).
FT                                {ECO:0000269|PubMed:22095935}.
FT                                /FTId=VAR_016186.
FT   VARIANT    3732   3732       I -> T (in dbSNP:rs1042025).
FT                                {ECO:0000269|PubMed:2883086,
FT                                ECO:0000269|PubMed:2994225,
FT                                ECO:0000269|PubMed:3030729,
FT                                ECO:0000269|PubMed:3763409}.
FT                                /FTId=VAR_019833.
FT   VARIANT    3801   3801       S -> T (in dbSNP:rs12713540).
FT                                /FTId=VAR_029349.
FT   VARIANT    3835   3835       I -> L. {ECO:0000269|PubMed:22095935}.
FT                                /FTId=VAR_067279.
FT   VARIANT    3921   3921       V -> I (in dbSNP:rs72654409).
FT                                {ECO:0000269|PubMed:9490296}.
FT                                /FTId=VAR_005027.
FT   VARIANT    3945   3945       T -> A (in dbSNP:rs1801698).
FT                                {ECO:0000269|PubMed:8889592}.
FT                                /FTId=VAR_005028.
FT   VARIANT    3949   3949       F -> L (in dbSNP:rs1042027).
FT                                {ECO:0000269|PubMed:2994225,
FT                                ECO:0000269|PubMed:3030729,
FT                                ECO:0000269|PubMed:3464946,
FT                                ECO:0000269|PubMed:3763409,
FT                                ECO:0000269|PubMed:3841481}.
FT                                /FTId=VAR_019834.
FT   VARIANT    3964   3964       Y -> F (in dbSNP:rs1126468).
FT                                {ECO:0000269|PubMed:2994225,
FT                                ECO:0000269|PubMed:3030729,
FT                                ECO:0000269|PubMed:3763409,
FT                                ECO:0000269|PubMed:3841481}.
FT                                /FTId=VAR_019835.
FT   VARIANT    4128   4128       V -> M (in dbSNP:rs1801703).
FT                                {ECO:0000269|PubMed:8889592}.
FT                                /FTId=VAR_005029.
FT   VARIANT    4181   4181       E -> K (in dbSNP:rs1042031).
FT                                {ECO:0000269|PubMed:22095935,
FT                                ECO:0000269|PubMed:2994225,
FT                                ECO:0000269|PubMed:3030729,
FT                                ECO:0000269|PubMed:3464946,
FT                                ECO:0000269|PubMed:3763409,
FT                                ECO:0000269|PubMed:3841481}.
FT                                /FTId=VAR_016187.
FT   VARIANT    4270   4270       R -> T (in dbSNP:rs1801702).
FT                                {ECO:0000269|PubMed:22095935}.
FT                                /FTId=VAR_016188.
FT   VARIANT    4314   4314       I -> V (in dbSNP:rs72654423).
FT                                {ECO:0000269|PubMed:22095935}.
FT                                /FTId=VAR_067280.
FT   VARIANT    4338   4338       S -> N (in dbSNP:rs1042034).
FT                                {ECO:0000269|PubMed:1979313,
FT                                ECO:0000269|PubMed:22095935,
FT                                ECO:0000269|PubMed:2883086,
FT                                ECO:0000269|PubMed:2932736,
FT                                ECO:0000269|PubMed:2994225,
FT                                ECO:0000269|PubMed:3030729,
FT                                ECO:0000269|PubMed:3464946,
FT                                ECO:0000269|PubMed:3652907,
FT                                ECO:0000269|PubMed:3759943,
FT                                ECO:0000269|PubMed:3763409,
FT                                ECO:0000269|Ref.6}.
FT                                /FTId=VAR_005030.
FT   VARIANT    4394   4394       V -> A (in dbSNP:rs12720843).
FT                                /FTId=VAR_029350.
FT   VARIANT    4481   4481       A -> T (in dbSNP:rs1801695).
FT                                {ECO:0000269|PubMed:22095935,
FT                                ECO:0000269|PubMed:8889592}.
FT                                /FTId=VAR_005031.
FT   VARIANT    4482   4482       I -> V. {ECO:0000269|PubMed:22095935}.
FT                                /FTId=VAR_067281.
FT   VARIANT    4484   4484       T -> M (in dbSNP:rs12713450).
FT                                /FTId=VAR_020140.
FT   MUTAGEN     483    483       D->N: Impairs protein secretion.
FT                                {ECO:0000269|PubMed:12551903}.
FT   MUTAGEN     483    483       D->Q: Does not affect protein secretion.
FT                                {ECO:0000269|PubMed:12551903}.
FT   MUTAGEN     490    490       R->A: Impairs protein secretion.
FT                                {ECO:0000269|PubMed:12551903}.
FT   MUTAGEN     490    490       R->K: Does not affect protein secretion.
FT                                {ECO:0000269|PubMed:12551903}.
FT   CONFLICT     11     13       Missing (in Ref. 5; AAB60718/CAA28420).
FT                                {ECO:0000305}.
FT   CONFLICT    329    329       L -> V (in Ref. 3; AAA35549).
FT                                {ECO:0000305}.
FT   CONFLICT    645    645       L -> I (in Ref. 3; AAA35549).
FT                                {ECO:0000305}.
FT   CONFLICT    704    704       L -> P (in Ref. 4; AAB04636).
FT                                {ECO:0000305}.
FT   CONFLICT    792    809       LQLLGKLLLMGARTLQGI -> SSSWKAASHGCPHSAGD
FT                                (in Ref. 12; AAA51759). {ECO:0000305}.
FT   CONFLICT    793    793       Q -> R (in Ref. 4; AAB04636).
FT                                {ECO:0000305}.
FT   CONFLICT    893    893       D -> K (in Ref. 13; AA sequence).
FT                                {ECO:0000305}.
FT   CONFLICT    919    919       A -> P (in Ref. 3; AAA35549).
FT                                {ECO:0000305}.
FT   CONFLICT   1109   1109       H -> D (in Ref. 5; CAA28420).
FT                                {ECO:0000305}.
FT   CONFLICT   1180   1180       T -> R (in Ref. 8; AAA51752).
FT                                {ECO:0000305}.
FT   CONFLICT   1271   1271       F -> S (in Ref. 4; AAB04636).
FT                                {ECO:0000305}.
FT   CONFLICT   1418   1418       F -> S (in Ref. 5; CAA28420).
FT                                {ECO:0000305}.
FT   CONFLICT   1445   1445       N -> I (in Ref. 8; AAA51752).
FT                                {ECO:0000305}.
FT   CONFLICT   1535   1535       G -> E (in Ref. 8; AAA51752).
FT                                {ECO:0000305}.
FT   CONFLICT   1867   1867       R -> G (in Ref. 4; AAB04636).
FT                                {ECO:0000305}.
FT   CONFLICT   2098   2098       N -> K (in Ref. 5; CAA28420).
FT                                {ECO:0000305}.
FT   CONFLICT   2218   2218       I -> T (in Ref. 4; AAB04636).
FT                                {ECO:0000305}.
FT   CONFLICT   2221   2221       N -> I (in Ref. 5; CAA28420).
FT                                {ECO:0000305}.
FT   CONFLICT   2324   2326       LIG -> PYW (in Ref. 16; AAA51741).
FT                                {ECO:0000305}.
FT   CONFLICT   2353   2353       Q -> H (in Ref. 16; AAA51741).
FT                                {ECO:0000305}.
FT   CONFLICT   2540   2540       G -> S (in Ref. 5; CAA28420).
FT                                {ECO:0000305}.
FT   CONFLICT   2718   2737       Missing (in Ref. 15; AAA51758).
FT                                {ECO:0000305}.
FT   CONFLICT   2933   2933       C -> S (in Ref. 4; AAB04636).
FT                                {ECO:0000305}.
FT   CONFLICT   3114   3114       H -> L (in Ref. 13; AA sequence).
FT                                {ECO:0000305}.
FT   CONFLICT   3131   3131       T -> R (in Ref. 13; AA sequence).
FT                                {ECO:0000305}.
FT   CONFLICT   3134   3134       E -> P (in Ref. 13; AA sequence).
FT                                {ECO:0000305}.
FT   CONFLICT   3137   3137       L -> R (in Ref. 13; AA sequence).
FT                                {ECO:0000305}.
FT   CONFLICT   3239   3239       H -> Q (in Ref. 5; CAA28420).
FT                                {ECO:0000305}.
FT   CONFLICT   3286   3286       L -> I (in Ref. 4; AAB04636).
FT                                {ECO:0000305}.
FT   CONFLICT   3291   3291       R -> L (in Ref. 15; AAA51758).
FT                                {ECO:0000305}.
FT   CONFLICT   3337   3337       I -> N (in Ref. 15; AAA51758).
FT                                {ECO:0000305}.
FT   CONFLICT   3431   3431       A -> P (in Ref. 4; AAB04636).
FT                                {ECO:0000305}.
FT   CONFLICT   3728   3728       D -> N (in Ref. 24; AAA51742).
FT                                {ECO:0000305}.
FT   CONFLICT   3782   3782       N -> T (in Ref. 4; AAB04636).
FT                                {ECO:0000305}.
FT   CONFLICT   3824   3824       Q -> R (in Ref. 5; CAA28420 and 23;
FT                                AAA51750). {ECO:0000305}.
FT   CONFLICT   3876   3876       V -> A (in Ref. 3; AAA35549 and 24;
FT                                AAA51742). {ECO:0000305}.
FT   CONFLICT   3911   3911       T -> Y (in Ref. 10; AA sequence).
FT                                {ECO:0000305}.
FT   CONFLICT   3983   3983       F -> S (in Ref. 24; AAA51742).
FT                                {ECO:0000305}.
FT   CONFLICT   4002   4002       A -> P (in Ref. 24; AAA51742).
FT                                {ECO:0000305}.
FT   CONFLICT   4110   4111       NN -> DH (in Ref. 3; AAA35549 and 24;
FT                                AAA51742). {ECO:0000305}.
FT   CONFLICT   4122   4122       Q -> E (in Ref. 3; AAA35549 and 24;
FT                                AAA51742). {ECO:0000305}.
FT   CONFLICT   4128   4128       V -> E (in Ref. 3; AAA35549 and 24;
FT                                AAA51742). {ECO:0000305}.
FT   CONFLICT   4133   4133       A -> G (in Ref. 3; AAA35549 and 24;
FT                                AAA51742). {ECO:0000305}.
FT   CONFLICT   4188   4188       H -> K (in Ref. 4; AAB04636).
FT                                {ECO:0000305}.
FT   CONFLICT   4217   4218       CT -> FP (in Ref. 26; AAA35548).
FT                                {ECO:0000305}.
FT   CONFLICT   4221   4221       I -> M (in Ref. 4; AAB04636).
FT                                {ECO:0000305}.
SQ   SEQUENCE   4563 AA;  515605 MW;  6800F94BF6ADF698 CRC64;
     MDPPRPALLA LLALPALLLL LLAGARAEEE MLENVSLVCP KDATRFKHLR KYTYNYEAES
     SSGVPGTADS RSATRINCKV ELEVPQLCSF ILKTSQCTLK EVYGFNPEGK ALLKKTKNSE
     EFAAAMSRYE LKLAIPEGKQ VFLYPEKDEP TYILNIKRGI ISALLVPPET EEAKQVLFLD
     TVYGNCSTHF TVKTRKGNVA TEISTERDLG QCDRFKPIRT GISPLALIKG MTRPLSTLIS
     SSQSCQYTLD AKRKHVAEAI CKEQHLFLPF SYKNKYGMVA QVTQTLKLED TPKINSRFFG
     EGTKKMGLAF ESTKSTSPPK QAEAVLKTLQ ELKKLTISEQ NIQRANLFNK LVTELRGLSD
     EAVTSLLPQL IEVSSPITLQ ALVQCGQPQC STHILQWLKR VHANPLLIDV VTYLVALIPE
     PSAQQLREIF NMARDQRSRA TLYALSHAVN NYHKTNPTGT QELLDIANYL MEQIQDDCTG
     DEDYTYLILR VIGNMGQTME QLTPELKSSI LKCVQSTKPS LMIQKAAIQA LRKMEPKDKD
     QEVLLQTFLD DASPGDKRLA AYLMLMRSPS QADINKIVQI LPWEQNEQVK NFVASHIANI
     LNSEELDIQD LKKLVKEALK ESQLPTVMDF RKFSRNYQLY KSVSLPSLDP ASAKIEGNLI
     FDPNNYLPKE SMLKTTLTAF GFASADLIEI GLEGKGFEPT LEALFGKQGF FPDSVNKALY
     WVNGQVPDGV SKVLVDHFGY TKDDKHEQDM VNGIMLSVEK LIKDLKSKEV PEARAYLRIL
     GEELGFASLH DLQLLGKLLL MGARTLQGIP QMIGEVIRKG SKNDFFLHYI FMENAFELPT
     GAGLQLQISS SGVIAPGAKA GVKLEVANMQ AELVAKPSVS VEFVTNMGII IPDFARSGVQ
     MNTNFFHESG LEAHVALKAG KLKFIIPSPK RPVKLLSGGN TLHLVSTTKT EVIPPLIENR
     QSWSVCKQVF PGLNYCTSGA YSNASSTDSA SYYPLTGDTR LELELRPTGE IEQYSVSATY
     ELQREDRALV DTLKFVTQAE GAKQTEATMT FKYNRQSMTL SSEVQIPDFD VDLGTILRVN
     DESTEGKTSY RLTLDIQNKK ITEVALMGHL SCDTKEERKI KGVISIPRLQ AEARSEILAH
     WSPAKLLLQM DSSATAYGST VSKRVAWHYD EEKIEFEWNT GTNVDTKKMT SNFPVDLSDY
     PKSLHMYANR LLDHRVPQTD MTFRHVGSKL IVAMSSWLQK ASGSLPYTQT LQDHLNSLKE
     FNLQNMGLPD FHIPENLFLK SDGRVKYTLN KNSLKIEIPL PFGGKSSRDL KMLETVRTPA
     LHFKSVGFHL PSREFQVPTF TIPKLYQLQV PLLGVLDLST NVYSNLYNWS ASYSGGNTST
     DHFSLRARYH MKADSVVDLL SYNVQGSGET TYDHKNTFTL SYDGSLRHKF LDSNIKFSHV
     EKLGNNPVSK GLLIFDASSS WGPQMSASVH LDSKKKQHLF VKEVKIDGQF RVSSFYAKGT
     YGLSCQRDPN TGRLNGESNL RFNSSYLQGT NQITGRYEDG TLSLTSTSDL QSGIIKNTAS
     LKYENYELTL KSDTNGKYKN FATSNKMDMT FSKQNALLRS EYQADYESLR FFSLLSGSLN
     SHGLELNADI LGTDKINSGA HKATLRIGQD GISTSATTNL KCSLLVLENE LNAELGLSGA
     SMKLTTNGRF REHNAKFSLD GKAALTELSL GSAYQAMILG VDSKNIFNFK VSQEGLKLSN
     DMMGSYAEMK FDHTNSLNIA GLSLDFSSKL DNIYSSDKFY KQTVNLQLQP YSLVTTLNSD
     LKYNALDLTN NGKLRLEPLK LHVAGNLKGA YQNNEIKHIY AISSAALSAS YKADTVAKVQ
     GVEFSHRLNT DIAGLASAID MSTNYNSDSL HFSNVFRSVM APFTMTIDAH TNGNGKLALW
     GEHTGQLYSK FLLKAEPLAF TFSHDYKGST SHHLVSRKSI SAALEHKVSA LLTPAEQTGT
     WKLKTQFNNN EYSQDLDAYN TKDKIGVELT GRTLADLTLL DSPIKVPLLL SEPINIIDAL
     EMRDAVEKPQ EFTIVAFVKY DKNQDVHSIN LPFFETLQEY FERNRQTIIV VLENVQRNLK
     HINIDQFVRK YRAALGKLPQ QANDYLNSFN WERQVSHAKE KLTALTKKYR ITENDIQIAL
     DDAKINFNEK LSQLQTYMIQ FDQYIKDSYD LHDLKIAIAN IIDEIIEKLK SLDEHYHIRV
     NLVKTIHDLH LFIENIDFNK SGSSTASWIQ NVDTKYQIRI QIQEKLQQLK RHIQNIDIQH
     LAGKLKQHIE AIDVRVLLDQ LGTTISFERI NDILEHVKHF VINLIGDFEV AEKINAFRAK
     VHELIERYEV DQQIQVLMDK LVELAHQYKL KETIQKLSNV LQQVKIKDYF EKLVGFIDDA
     VKKLNELSFK TFIEDVNKFL DMLIKKLKSF DYHQFVDETN DKIREVTQRL NGEIQALELP
     QKAEALKLFL EETKATVAVY LESLQDTKIT LIINWLQEAL SSASLAHMKA KFRETLEDTR
     DRMYQMDIQQ ELQRYLSLVG QVYSTLVTYI SDWWTLAAKN LTDFAEQYSI QDWAKRMKAL
     VEQGFTVPEI KTILGTMPAF EVSLQALQKA TFQTPDFIVP LTDLRIPSVQ INFKDLKNIK
     IPSRFSTPEF TILNTFHIPS FTIDFVEMKV KIIRTIDQML NSELQWPVPD IYLRDLKVED
     IPLARITLPD FRLPEIAIPE FIIPTLNLND FQVPDLHIPE FQLPHISHTI EVPTFGKLYS
     ILKIQSPLFT LDANADIGNG TTSANEAGIA ASITAKGESK LEVLNFDFQA NAQLSNPKIN
     PLALKESVKF SSKYLRTEHG SEMLFFGNAI EGKSNTVASL HTEKNTLELS NGVIVKINNQ
     LTLDSNTKYF HKLNIPKLDF SSQADLRNEI KTLLKAGHIA WTSSGKGSWK WACPRFSDEG
     THESQISFTI EGPLTSFGLS NKINSKHLRV NQNLVYESGS LNFSKLEIQS QVDSQHVGHS
     VLTAKGMALF GEGKAEFTGR HDAHLNGKVI GTLKNSLFFS AQPFEITAST NNEGNLKVRF
     PLRLTGKIDF LNNYALFLSP SAQQASWQVS ARFNQYKYNQ NFSAGNNENI MEAHVGINGE
     ANLDFLNIPL TIPEMRLPYT IITTPPLKDF SLWEKTGLKE FLKTTKQSFD LSVKAQYKKN
     KHRHSITNPL AVLCEFISQS IKSFDRHFEK NRNNALDFVT KSYNETKIKF DKYKAEKSHD
     ELPRTFQIPG YTVPVVNVEV SPFTIEMSAF GYVFPKAVSM PSFSILGSDV RVPSYTLILP
     SLELPVLHVP RNLKLSLPDF KELCTISHIF IPAMGNITYD FSFKSSVITL NTNAELFNQS
     DIVAHLLSSS SSVIDALQYK LEGTTRLTRK RGLKLATALS LSNKFVEGSH NSTVSLTTKN
     MEVSVATTTK AQIPILRMNF KQELNGNTKS KPTVSSSMEF KYDFNSSMLY STAKGAVDHK
     LSLESLTSYF SIESSTKGDV KGSVLSREYS GTIASEANTY LNSKSTRSSV KLQGTSKIDD
     IWNLEVKENF AGEATLQRIY SLWEHSTKNH LQLEGLFFTN GEHTSKATLE LSPWQMSALV
     QVHASQPSSF HDFPDLGQEV ALNANTKNQK IRWKNEVRIH SGSFQSQVEL SNDQEKAHLD
     IAGSLEGHLR FLKNIILPVY DKSLWDFLKL DVTTSIGRRQ HLRVSTAFVY TKNPNGYSFS
     IPVKVLADKF IIPGLKLNDL NSVLVMPTFH VPFTDLQVPS CKLDFREIQI YKKLRTSSFA
     LNLPTLPEVK FPEVDVLTKY SQPEDSLIPF FEITVPESQL TVSQFTLPKS VSDGIAALDL
     NAVANKIADF ELPTIIVPEQ TIEIPSIKFS VPAGIVIPSF QALTARFEVD SPVYNATWSA
     SLKNKADYVE TVLDSTCSST VQFLEYELNV LGTHKIEDGT LASKTKGTFA HRDFSAEYEE
     DGKYEGLQEW EGKAHLNIKS PAFTDLHLRY QKDKKGISTS AASPAVGTVG MDMDEDDDFS
     KWNFYYSPQS SPDKKLTIFK TELRVRESDE ETQIKVNWEE EAASGLLTSL KDNVPKATGV
     LYDYVNKYHW EHTGLTLREV SSKLRRNLQN NAEWVYQGAI RQIDDIDVRF QKAASGTTGT
     YQEWKDKAQN LYQELLTQEG QASFQGLKDN VFDGLVRVTQ EFHMKVKHLI DSLIDFLNFP
     RFQFPGKPGI YTREELCTMF IREVGTVLSQ VYSKVHNGSE ILFSYFQDLV ITLPFELRKH
     KLIDVISMYR ELLKDLSKEA QEVFKAIQSL KTTEVLRNLQ DLLQFIFQLI EDNIKQLKEM
     KFTYLINYIQ DEINTIFSDY IPYVFKLLKE NLCLNLHKFN EFIQNELQEA SQELQQIHQY
     IMALREEYFD PSIVGWTVKY YELEEKIVSL IKNLLVALKD FHSEYIVSAS NFTSQLSSQV
     EQFLHRNIQE YLSILTDPDG KGKEKIAELS ATAQEIIKSQ AIATKKIISD YHQQFRYKLQ
     DFSDQLSDYY EKFIAESKRL IDLSIQNYHT FLIYITELLK KLQSTTVMNP YMKLAPGELT
     IIL
//
